Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
February 21, 2017OncoCyte Receives $2 Million in Proceeds from Early Exercise of Warrants
Completes Sample Collection and Processing for the 300-Patient Study of its Lung Cancer Diagnostic Test ALAMEDA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $2,031,250 through the early exercise of 625,000 common stock purchase warrants.  Each warrant was exercised to purchase one share of common stock for $3.25 per share. The warrants were issued durin... 
Printer Friendly Version
February 13, 2017OncoCyte Corporation to Present at the 19th Annual BIO CEO & Investor Conference and the 2017 Disruptive Growth & Healthcare Conference
ALAMEDA, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th, at 10:30 a.m. ET, where OncoCyte is also being recognized and honored as the Buzz of BIO winner in the “diagnostics ... 
Printer Friendly Version
February 03, 2017Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
- Warrant extension follows positive recent update on further motor function improvements observed in SCiStar study patients dosed with AST-OPC1 - - Cash position significantly improved from the same time last year - FREMONT, Calif., Feb. 3, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced the company is extending the expiration date of certain warrants. The decision to ex... 
Printer Friendly Version
January 27, 2017OncoCyte Wins Buzz of BIO for the 2017 BIO CEO & Investor Conference
ALAMEDA, Calif., Jan. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that the Biotechnology Innovation Organization (BIO) has recognized OncoCyte Corporation as the Buzz of BIO winner in the “diagnostics and beyond category” for the 2017 BIO CEO & Investor Conference taking place February 13–14 at the Waldorf Astoria in New York. Nominated and selected by an online vote, contest winners are... 
Printer Friendly Version
January 24, 2017Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
-Management to discuss results on conference call today at 5:00 p.m. Eastern / 2:00 p.m. Pacific- -SCiStar lead investigator Richard Fessler, MD, and John Steeves, Ph.D., Co-Chair of the Spinal Cord Outcomes Partnership Endeavor (SCOPE), will join Asterias management on the call- FREMONT, Calif., Jan. 24, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced positive efficacy... 
Printer Friendly Version
January 24, 2017OncoCyte to Present Interim Data from Its Lung Cancer Diagnostic Test Study at the American Thoracic Society Conference May 22, 2017
ALAMEDA, Calif., Jan. 24, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that its abstract on interim data from the Company’s lung cancer diagnostic test study has been selected for presentation in a poster discussion session at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.C.  The discussion will be led by Dr. Anil Vachani, an Associate Professor of Medicin... 
Printer Friendly Version
January 04, 2017OncoCyte Provides Updated Timelines on Diagnostic Test Development and Commercialization Plans
Breast Cancer Test Development Three to Six Months Ahead of Schedule; Commercial Launch Possible in Mid to Late 2018 Lung Cancer Test Development Two to Three Months Behind Schedule; Commercial Launch Planned for Second Half of 2017 ALAMEDA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood and urine based tests for the early detection of cancer, today provided an update on the development of its product portfolio that c... 
Printer Friendly Version